The Manufacturers Life Insurance Company Sells 21,337 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

The Manufacturers Life Insurance Company lessened its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 14.9% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 122,094 shares of the biopharmaceutical company's stock after selling 21,337 shares during the period. The Manufacturers Life Insurance Company owned approximately 0.21% of Agios Pharmaceuticals worth $4,012,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the company. Venturi Wealth Management LLC purchased a new stake in Agios Pharmaceuticals during the fourth quarter worth about $33,000. Wingate Wealth Advisors Inc. acquired a new position in Agios Pharmaceuticals during the fourth quarter worth about $53,000. Sterling Capital Management LLC raised its position in Agios Pharmaceuticals by 818.0% during the fourth quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock worth $59,000 after acquiring an additional 1,587 shares during the last quarter. KBC Group NV raised its position in Agios Pharmaceuticals by 30.5% during the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock worth $86,000 after acquiring an additional 611 shares during the last quarter. Finally, AlphaQuest LLC raised its position in Agios Pharmaceuticals by 106.2% during the fourth quarter. AlphaQuest LLC now owns 4,540 shares of the biopharmaceutical company's stock worth $149,000 after acquiring an additional 2,338 shares during the last quarter.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. StockNews.com upgraded shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday. HC Wainwright began coverage on shares of Agios Pharmaceuticals in a report on Monday, February 24th. They issued a "buy" rating and a $58.00 target price for the company. Finally, Scotiabank reduced their target price on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating on the stock in a report on Friday, May 2nd. Five analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, Agios Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $56.00.

Insider Transactions at Agios Pharmaceuticals

In related news, Director Jacqualyn A. Fouse sold 7,497 shares of the firm's stock in a transaction on Thursday, April 10th. The stock was sold at an average price of $25.90, for a total value of $194,172.30. Following the completion of the transaction, the director now directly owns 149,220 shares of the company's stock, valued at $3,864,798. This trade represents a 4.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 4.30% of the stock is currently owned by corporate insiders.

Agios Pharmaceuticals Stock Performance

Shares of NASDAQ AGIO traded down $0.37 during mid-day trading on Tuesday, reaching $28.77. The company had a trading volume of 352,563 shares, compared to its average volume of 695,282. The stock has a fifty day moving average of $29.14 and a two-hundred day moving average of $37.06. The company has a market capitalization of $1.67 billion, a price-to-earnings ratio of 2.54 and a beta of 0.77. Agios Pharmaceuticals, Inc. has a 12-month low of $23.42 and a 12-month high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) EPS for the quarter, beating the consensus estimate of ($1.80) by $0.25. The company had revenue of $8.73 million for the quarter, compared to the consensus estimate of $9.86 million. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. Sell-side analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.